| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lexaria Bioscience Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.49 |
| 52 Week High | US$6.85 |
| 52 Week Low | US$0.65 |
| Beta | 0.95 |
| 1 Month Change | 2.05% |
| 3 Month Change | 122.29% |
| 1 Year Change | 115.43% |
| 3 Year Change | -30.62% |
| 5 Year Change | -87.75% |
| Change since IPO | 6.64% |
Recent News & Updates
Recent updates
Lexaria Bioscience gets third patent granted in Japan
Jul 14Lexaria Bioscience's DehydraTECH licensee Cannadips expands internationally
Jul 07Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans?
Apr 15
We Think Lexaria Bioscience (NASDAQ:LEXX) Can Afford To Drive Business Growth
Dec 07Lexaria Hits New 52-Week High With Positive Data On Enhanced Treatment For COVID-19
Jul 22Shareholder Returns
| LEXX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 58.6% | 1.0% | -0.7% |
| 1Y | 115.4% | 11.6% | 22.3% |
Return vs Industry: LEXX exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: LEXX exceeded the US Market which returned 22.3% over the past year.
Price Volatility
| LEXX volatility | |
|---|---|
| LEXX Average Weekly Movement | 25.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LEXX's share price has been volatile over the past 3 months.
Volatility Over Time: LEXX's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | Chris Bunka | lexariabioscience.com |
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company’s DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids.
Lexaria Bioscience Corp. Fundamentals Summary
| LEXX fundamental statistics | |
|---|---|
| Market cap | US$39.82m |
| Earnings (TTM) | -US$5.44m |
| Revenue (TTM) | US$404.73k |
111.1x
P/S Ratio-8.3x
P/E RatioIs LEXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LEXX income statement (TTM) | |
|---|---|
| Revenue | US$404.73k |
| Cost of Revenue | US$17.57k |
| Gross Profit | US$387.16k |
| Other Expenses | US$5.83m |
| Earnings | -US$5.44m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 95.66% |
| Net Profit Margin | -1,344.04% |
| Debt/Equity Ratio | 0% |
How did LEXX perform over the long term?
See historical performance and comparison